Director and Chair of the Scientific Advisory Board Wang Xiaodong filed a Form 4 with the SEC on October 29, 2026, disclosing the exercise of a share option and the subsequent sale of 31,028 American Depositary Shares of BeOne Medicines Ltd. (NASDAQ:ONC) on October 27, 2026, pursuant to a Rule 10b5-1 trading plan.

Key Highlights

  • Option exercise: Wang Xiaodong exercised a share option (transaction code M) on October 27, 2026, acquiring 31,028 American Depositary Shares at an exercise price of $36.9 each.
  • Full ADS position disposed: All 31,028 acquired ADS were sold on October 27, 2026, across eleven separate sale tranches, leaving a direct ADS balance of zero.
  • Sale price range: The weighted average sale prices across tranches ranged from $355.5595 to $366.2205 per ADS, with individual transaction prices spanning $355.08 to $366.45.
  • 10b5-1 plan: According to the filing, all sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2026.
  • Underlying option extinguished: The share option exercised carried an exercise price of $2.84 per ordinary share and an expiration date of November 15, 2026; following the exercise, zero options remain directly held.
  • Remaining beneficial ownership: Following the transactions, Wang Xiaodong directly holds 4,588,113 ordinary shares, with additional indirect holdings of 1,025,063 ordinary shares (family trust), 3,953,100 ordinary shares (Wang Investment LLC), and 50 ordinary shares held by his spouse, all for which the filing states he disclaims beneficial ownership.
  • Each ADS represents 13 ordinary shares, as stated in the filing footnotes.

Wang Xiaodong's October 27 Option Exercise and ADS Sales at BeOne Medicines

According to the Form 4 filed with the SEC, Wang Xiaodong, who serves as both a Director and Chair of the Scientific Advisory Board of BeOne Medicines Ltd. (NASDAQ:ONC), executed a two-step transaction on October 27, 2026. He first exercised a share option (transaction code M) to acquire 31,028 American Depositary Shares at a price of $36.9 per ADS. The underlying option had an exercise price of $2.84 per ordinary share and was set to expire on November 15, 2026. Following the exercise, his direct ADS holdings stood at 31,028 before any sales.

The filing discloses that Wang then disposed of the entire 31,028 ADS through eleven sale tranches on the same date, all under a Rule 10b5-1 trading plan he adopted on June 9, 2026. Sale prices, each reported as a weighted average, ranged from $355.5595 (880 ADS) to $366.2205 (6,903 ADS) per ADS. Individual transaction prices within each tranche varied, with the full range spanning $355.08 to $366.45, and the filing states that Wang has undertaken to provide full per-share pricing detail to the issuer, the SEC, or any security holder upon request.

After all reported transactions, Wang Xiaodong holds zero ADS directly. His direct ordinary share position remains at 4,588,113. The filing also lists indirect holdings of 1,025,063 ordinary shares through a family trust (beneficiaries are family members), 3,953,100 ordinary shares through Wang Investment LLC (in which 99% of interests are owned by two grantor retained annuity trusts for which his wife is a trustee), and 50 ordinary shares held by his spouse. The filing states he disclaims beneficial ownership of all three indirect positions.

What Was Disclosed

Wang Xiaodong's Form 4 covers a same-day option exercise and full sale of 31,028 ADS in BeOne Medicines on October 27, 2026, conducted under a pre-established 10b5-1 plan, with zero direct ADS remaining after the transactions.